HJ-037
/ Chengdu Huajian Future Science and Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical evaluation of combination therapy of HJ-037 with anti-PD-1 antibody treating KRASG12C mutated tumors
(AACR 2025)
- "Preclinical study results indicate that the combination therapy of HJ-037 with PD-1 inhibitor could enhance the intensity and duration of antitumor activity compared to monotherapy, with satisfactory safety, therefore possessing a better potential for the treatment of cancer patients harboring KRASG12C mutation."
Combination therapy • IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1